EN DE
STOCK COMPARISON

Johnson & Johnson vs Thermo Fisher Scientific: Fair Value & Quality

Both stocks run through our valuation models. Here is how Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO) compare, as of Aug 13, 2026.

As of Aug 13, 2026, Fair Value Calculator sees Johnson & Johnson as the less overvalued of the two: Johnson & Johnson trades at $261 versus a fair value of $169 (-35%), while Thermo Fisher Scientific trades at $603 versus $308 (-49%).
Johnson & Johnson
JNJ · USD · Health Care
-35%
upside to fair value
overvalued
Price$261
Fair Value$169
Quality81/100
Thermo Fisher Scientific
TMO · USD · Health Care
-49%
upside to fair value
overvalued
Price$603
Fair Value$308
Quality63/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Johnson & JohnsonThermo Fisher Scientific
Valuation
29.4×P/E (TTM)29.5×
6.34×P/S (TTM)4.41×
7.49×P/B3.74×
18.4×EV/EBITDA20.0×
4.95×PEG1.74×
2.0%Dividend yield0.3%
$5.20Dividend per share$1.76
Profitability
22%Net margin15%
27%Operating margin18%
26%Return on equity14%
8%Return on assets5%
Growth
10%Revenue growth (YoY)6%
5.6%Avg. growth/yr (3Y)-0.3%
2.7%Avg. growth/yr (5Y)6.7%
Balance & size
0.48×Debt / equity0.67×
$611BMarket cap$199B
healthyGrowth qualityhealthy

Johnson & Johnson leads: 10 to 4 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Johnson & Johnsonof which business quality 76 · market factors 85 Thermo Fisher Scientificof which business quality 60 · market factors 69
ProfitabilityMargins and returns on capital today
74
43
Quality GrowthAre margins and returns improving?
73
31
CashflowEarnings quality: real cash, not paper profit
70
62
Fin. StrengthBalance sheet, leverage, solvency risk
72
60
InvestmentDisciplined investing over empire-building
87
79
Low VolatilityCalm price path (market factor)
96
69
MomentumPrice trend over the last 3–12 months (market factor)
72
64
52W MomentumDistance to the 52-week high (market factor)
94
77
Net IssuanceBuybacks instead of dilution
90
97

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Johnson & Johnson

DCF Models$171
Earnings-Based$73.34
Dividend Discount$93.41
Multiples$163
Asset-Based$22.70
Growth DCF$129
Economic Profit$102
Growth Earnings$207

26 of 26 models see the stock below the current price.

Thermo Fisher Scientific

DCF Models$354
Earnings-Based$203
Multiples$308
Asset-Based$96.29
Growth DCF$288
Economic Profit$159
Growth Earnings$341

24 of 24 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Johnson & Johnson
Bear $106Fair Value $169Bull $255
$261 = current price (white tick)
Thermo Fisher Scientific
Bear $171Fair Value $308Bull $385
$603 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Johnson & Johnson · Health Care

Quality score81 · Top 25%
Fair value upside-35% · below median

Thermo Fisher Scientific · Health Care

Quality score63 · Top 25%
Fair value upside-49% · below median

Bottom line

As of Aug 13, 2026, Fair Value Calculator sees Johnson & Johnson as the less overvalued of the two: Johnson & Johnson trades at $261 versus a fair value of $169 (-35%), while Thermo Fisher Scientific trades at $603 versus $308 (-49%).

Johnson & Johnson has the higher quality score (81/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.